Moody's: FDA Approval of Generic Nilandron is Credit Negative for Concordia; no change to rating or outlook

New York, July 20, 2016 — Moody’s Investors Service commented that the FDA approval of ANI Pharmaceuticals’ (not rated …
(Orginal – Story lesen…)

This website stores some user agent data. These data are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to opt-out of any future tracking, a cookie will be set up in your browser to remember this choice for one year. I Agree, Deny
720